SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-000967
Filing Date
2022-01-14
Accepted
2022-01-14 17:01:21
Documents
16
Period of Report
2022-01-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20220114.htm   iXBRL 8-K 63194
2 EX-5.1 ex_51opinion.htm EX-5.1 16354
3 EX-10.1 ex_101purchaseagreement.htm EX-10.1 303355
4 EX-10.2 ex_102registrationrights.htm EX-10.2 121824
8 image_1a.jpg GRAPHIC 8359
  Complete submission text file 0001628280-22-000967.txt   748094

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20220114.xsd EX-101.SCH 1914
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20220114_lab.xml EX-101.LAB 25998
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20220114_pre.xml EX-101.PRE 13731
10 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20220114_htm.xml XML 11887
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 22532524
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences